Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $34.00.

ARCT has been the subject of a number of research analyst reports. Roth Mkm began coverage on Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target for the company. Piper Sandler reduced their price target on shares of Arcturus Therapeutics from $140.00 to $72.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Citigroup lowered their price objective on shares of Arcturus Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright decreased their price target on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently bought and sold shares of the company. Osaic Holdings Inc. lifted its position in shares of Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Arcturus Therapeutics during the fourth quarter worth $64,000. Intech Investment Management LLC purchased a new stake in shares of Arcturus Therapeutics during the fourth quarter worth $70,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Arcturus Therapeutics by 65.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,737 shares in the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $7.67 on Monday. The stock has a 50 day moving average of $7.06 and a 200 day moving average of $11.74. The firm has a market capitalization of $217.90 million, a price-to-earnings ratio of -3.12 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $5.85 and a fifty-two week high of $24.17.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.